| Schedule of research and development expense |
| | | | | | | 2025 | | 2024 | | | $ | | $ | | | (Restated – see Note 4) | | (Restated – see Note 4) | Research and Development Expenses | | | | | Amortization of intangible asset | | 55,795 | | 55,795 | Preclinical development | | 726,790 | | 2,085,692 | Chemistry, manufacturing and controls | | 3,391,560 | | 1,571,048 | Licensing and patent legal fees | | 449,183 | | 535,066 | Clinical and regulatory | | 2,924,649 | | 5,845,332 | Salaries and benefits | | 4,356,192 | | 3,702,721 | Stock-based compensation | | 1,128,814 | | 1,003,970 | Other research and development | | 433,249 | | 705,722 | | | 13,466,234 | | 15,505,346 |
|
| Schedule of general and administrative expense |
| | | | | | | 2025 | | 2024 | | | $ | | $ | | | (Restated – see Note 4) | | (Restated – see Note 4) | General and Administration Expenses | | | | | Depreciation expense | | — | | 28,003 | Legal, professional and finance | | 2,236,274 | | 831,755 | Investor and public relations | | 1,423,329 | | 1,238,152 | Salaries and benefits | | 2,941,903 | | 1,958,369 | Stock-based compensation | | 2,474,805 | | 3,526,021 | Other general and administrative | | 745,413 | | 578,770 | | | 9,821,724 | | 8,161,070 |
|